Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.0K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

4.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Learning millisecond protein dynamics from what is missing in NMR spectra.

bioRxiv : the preprint server for biology·2026
Same author

Stochastic models indicate rapid smallpox spread and mass mortality of Indigenous Australians after colonial exposure.

Nature human behaviour·2026
Same author

An uncommon skin manifestation after radial artery catheterization.

Cleveland Clinic journal of medicine·2026
Same author

Protocol for assessment of pain biomarkers in orthopaedic patients undergoing total knee arthroplasty in a tertiary care hospital and neuroimmunopharmacology laboratory in South Australia: a cross-sectional matched-subject observational study.

BMJ open·2026
Same author

Joint Reaction Forces Decrease Following Total Knee Arthroplasty up to 12-Months Post-Surgery.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society·2026
Same author

Direct anterior approach for total hip arthroplasty with patients in the lateral decubitus vs supine position: A systematic review and meta-analysis.

Journal of orthopaedics·2026

Related Experiment Video

Updated: Mar 14, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.9K

Drug targets evolve, and so should the methods.

Christopher Wilson1, Roman V Agafonov1, Dorothee Kern1

  • 1Howard Hughes Medical Institute, Department of Biochemistry, Brandeis University , Waltham, MA, USA .

Molecular & Cellular Oncology
|September 22, 2016
PubMed
Summary

Developing targeted anticancer drugs like kinase inhibitors is promising but challenging. This study shows how combining biophysical methods with genomics and molecular evolution can overcome limitations in designing effective kinase inhibitors.

Keywords:
Cancer drugsGleevecdrug designevolutionprotein kinases

More Related Videos

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.9K

Related Experiment Videos

Last Updated: Mar 14, 2026

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

17.9K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K
Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

3.9K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Genomics

Background:

  • Targeted anticancer therapies, specifically kinase inhibitors, offer a promising avenue for cancer treatment.
  • Despite the potential, the development of specific kinase inhibitors has faced significant challenges, limiting clinical success.

Purpose of the Study:

  • To explore novel strategies for overcoming limitations in the design of specific kinase inhibitors.
  • To demonstrate the utility of integrating diverse scientific disciplines for advancing anticancer drug discovery.

Main Methods:

  • Utilized a combination of established and contemporary biophysical techniques.
  • Incorporated recent advancements in genomics for target identification and validation.
  • Applied principles of molecular evolution to refine inhibitor design and specificity.

Main Results:

  • Successfully demonstrated a synergistic approach combining biophysical, genomic, and evolutionary methods.
  • Showcased the potential to enhance the specificity and efficacy of kinase inhibitors.
  • Provided a framework for overcoming existing hurdles in anticancer drug development.

Conclusions:

  • The integration of traditional and modern biophysical tools with genomics and molecular evolution presents a powerful strategy.
  • This multidisciplinary approach can significantly improve the design and development of specific kinase inhibitors for cancer therapy.
  • Overcoming limitations in kinase inhibitor development is achievable through innovative, combined methodologies.